This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biomarin Pharmaceutical Inc.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Carlos Fabricio Santamaria: Innovator in Enzyme Detection
Introduction
Carlos Fabricio Santamaria is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of enzyme detection, particularly in relation to phenylalanine ammonia-lyase. His work is crucial for advancing therapies for various diseases, including phenylketonuria and cancer.
Latest Patents
Carlos holds a patent for "Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase." This patent outlines methods for detecting the presence of a pegylated enzyme, enzyme-specific antibodies, or polyethylene glycol-specific antibodies in samples such as bodily fluids or tissues. The enzyme in focus is phenylalanine ammonia-lyase (PAL), which is administered as part of enzyme substitution therapy.
Career Highlights
Carlos is currently employed at BioMarin Pharmaceutical Inc., where he continues to innovate in the field of biotechnology. His work has the potential to improve treatment options for patients suffering from metabolic disorders and certain types of cancer.
Collaborations
Carlos has collaborated with notable colleagues, including Erik Damien Foehr and Bin Zhao, who contribute to the research and development efforts at BioMarin Pharmaceutical Inc.
Conclusion
Carlos Fabricio Santamaria is a key figure in the field of enzyme detection, with a focus on improving therapeutic options for patients. His innovative work and collaborations highlight the importance of research in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile